Pathological factors that influence prognosis in stage A prostatic cancer: the influence of extent versus grade
- PMID: 7218450
- DOI: 10.1016/s0022-5347(17)55092-2
Pathological factors that influence prognosis in stage A prostatic cancer: the influence of extent versus grade
Abstract
To determine the pathologic factors useful in predicting prognosis in patients with stage A prostatic cancer we studied 117 patients followed for 2 to 15 years. Since no patient was treated until progression of disease occurred we were able to correlate pathologic findings with the natural history of the disease in an untreated population of patients. In 14 patients (12 per cent) extensive local (2) or metastatic (12) disease developed. Because 12 of the 14 patients had progression of the disease within 4 years we thought than an analysis of all patients followed for 4 years would be useful. Extent and grade of disease were the 2 factors that most accurately predicted progression. No patient with a low grade lesion (Hopkins grade 1 or Gleason total score 2 to 4) had progression and only 2 per cent of patients with less than 5 per cent cancer had progression. These patients were classified as stage A1 and 60 per cent of all patients were in this category. We believe that these patients require no further therapy. Of the patients with more than 5 per cent cancer 32 per cent had progression and 17 per cent of the patients with either Hopkins grade 2 to 3 disease or Gleason total score more than 4 had progression. These patients were classified as stage A2 and their optimal management remains to be determined.
Similar articles
-
Prognosis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended followup.J Urol. 1986 Oct;136(4):837-9. doi: 10.1016/s0022-5347(17)45097-x. J Urol. 1986. PMID: 3761442
-
Operable prostatic carcinoma: correlations among clinical stage, pathological stage, gleason histological score and early disease-free survival.J Urol. 1985 Jan;133(1):49-52. doi: 10.1016/s0022-5347(17)48778-7. J Urol. 1985. PMID: 3964879
-
Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4.J Urol. 2001 Nov;166(5):1692-7. J Urol. 2001. PMID: 11586204
-
Low Gleason score prostatic adenocarcinomas are no longer viable entities.Histopathology. 2007 May;50(6):683-90. doi: 10.1111/j.1365-2559.2007.02596.x. Histopathology. 2007. PMID: 17493232 Review.
-
[Natural history of cancer of the prostate].J Urol (Paris). 1987;93(8):469-74. J Urol (Paris). 1987. PMID: 3326898 Review. French.
Cited by
-
Tumor extent in radical prostatectomy specimens: is it an independent prognostic factor for biochemical (PSA) progression following surgery?Int Urol Nephrol. 2011 Jun;43(2):417-22. doi: 10.1007/s11255-010-9818-4. Epub 2010 Aug 10. Int Urol Nephrol. 2011. PMID: 20697812
-
Long-term survival of stage A prostate carcinoma, atypical hyperplasia/adenosis and BPH.Br J Cancer. 1994 Jun;69(6):1098-101. doi: 10.1038/bjc.1994.215. Br J Cancer. 1994. PMID: 7515262 Free PMC article.
-
Comparative clinical features of stage A1 and stage A2 prostate cancers. Is the concept of stage A changing from the current status?Int Urol Nephrol. 1995;27(5):575-85. doi: 10.1007/BF02564744. Int Urol Nephrol. 1995. PMID: 8775042
-
Periodic health examination, 1991 update: 3. Secondary prevention of prostate cancer. Canadian Task Force on the Periodic Health Examination.CMAJ. 1991 Sep 1;145(5):413-28. CMAJ. 1991. PMID: 1878824 Free PMC article. Review. No abstract available.
-
Incidental versus manifest prostatic carcinoma.Int Urol Nephrol. 1987;19(2):175-8. doi: 10.1007/BF02550470. Int Urol Nephrol. 1987. PMID: 2444546
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical